FDA ad­comm takes down Se­cu­ra Bio's leukemia drug af­ter fi­nal tri­al re­sults show po­ten­tial OS detri­ment

The FDA’s On­co­log­ic Drugs Ad­vi­so­ry Com­mit­tee on Fri­day vot­ed 8-4 against the ben­e­fit-risk pro­file of Se­cu­ra Bio’s PI3K in­hibitor Copik­tra (du­velis­ib), which won ap­proval in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.